Constitutional symptom (HP:0025142)
A symptom or manifestation indicating a systemic or general effect of a disease and that may affect the general well-being or status of an individual.
Synonyms: No synonyms found for this term.
Comment: Note that we use the preferred term label constitutional symptom because this reflects common usage, but we do not restrict the term or its descendents to the narrow meaning of symptom, i.e., a complaint related by a patient to a physician. There is no generally accepted classification of what defines a constitutional symptom, but examples include weight loss, fatigue, general weakness, night sweats, shaking, chills, fever, and vomiting.
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Cardiac muscle contraction | 2.733e-15 | 4.192e-14 | 580.71 | 19473.01 |
| 2 | Hypertrophic cardiomyopathy | 3.494e-15 | 4.192e-14 | 559.63 | 18629.01 |
| 3 | Dilated cardiomyopathy | 5.569e-15 | 4.455e-14 | 521.75 | 17124.60 |
| 4 | Adrenergic signaling in cardiomyocytes | 1.365e-13 | 8.188e-13 | 323.84 | 9593.14 |
| 5 | Viral myocarditis | 0.0003921 | 0.001569 | 85.91 | 673.90 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | heart contraction (GO:0060047) | 2.480e-24 | 4.242e-22 | 5613.19 | 305096.95 |
| 2 | cardiac muscle contraction (GO:0060048) | 1.284e-21 | 1.098e-19 | 3071.38 | 147746.28 |
| 3 | striated muscle contraction (GO:0006941) | 7.348e-20 | 4.188e-18 | 1734.26 | 76406.89 |
| 4 | ventricular cardiac muscle tissue morphogenesis (GO:0055010) | 2.534e-18 | 1.083e-16 | 1725.20 | 69899.68 |
| 5 | ventricular cardiac muscle tissue development (GO:0003229) | 4.171e-16 | 1.426e-14 | 1576.66 | 55834.51 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | myosin heavy chain binding (GO:0032036) | 3.147e-9 | 1.070e-7 | 2141.36 | 41921.23 |
| 2 | voltage-gated sodium channel activity involved in cardiac muscle cell action potential (GO:0086006) | 0.002498 | 0.009436 | 555.17 | 3326.77 |
| 3 | nitric-oxide synthase binding (GO:0050998) | 0.003495 | 0.01188 | 370.07 | 2093.27 |
| 4 | actin monomer binding (GO:0003785) | 0.00006709 | 0.0006402 | 217.03 | 2085.58 |
| 5 | calcium channel inhibitor activity (GO:0019855) | 0.005488 | 0.01435 | 222.00 | 1155.57 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | cardiac myofibril (GO:0097512) | 8.995e-10 | 1.394e-8 | 4283.14 | 89214.48 |
| 2 | myofibril (GO:0030016) | 7.595e-13 | 2.354e-11 | 907.64 | 25328.60 |
| 3 | muscle myosin complex (GO:0005859) | 4.082e-8 | 4.218e-7 | 713.50 | 12139.53 |
| 4 | junctional sarcoplasmic reticulum membrane (GO:0014701) | 0.000008085 | 0.00006266 | 713.68 | 8368.26 |
| 5 | myosin filament (GO:0032982) | 0.002997 | 0.009289 | 444.11 | 2580.41 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| MYH6 | – |
| MYL2 | – |
| MYBPC3 | – |
| TNNI3 | – |
| MYH7 | – |
| SCN5A | INDECAINIDE, BENZONATATE, FOSPHENYTOIN, MORICIZINE, HEXYLCAINE, PROCAINAMIDE, MEXILETINE, DISOPYRAMIDE |
| RYR2 | PROCAINE |
| MYL3 | – |
| LDB3 | – |
| CASQ2 | – |
